Intriguingly, despite its inability to inhibit COX-2, DMC is able to faithfully mimic – without exception – all of celecoxib's numerous anti-tumor effects that have been investigated so far, including the reduction of neovascularization and the inhibition of experimental tumor growth in various in vivo tumor models [21,25,26,28-32]. This evidence concerns the gene PTGS2 and neoplasm.